SCHEMBL6565697

SCHEMBL6565697

O=[N+]([O-])c1ccc(Cl)c(S(=O)(=O)NCCCN2CCOCC2)c1Cl

nearest known ligand 0.71

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.71
KMT2A Q03164 4/20 0.58
ALDH1A1 P00352 2/20 0.56
PKM P14618 2/20 0.52
POLB P06746 3/20 0.49
LMNA P02545 1/20 0.49
MAPT P10636 1/20 0.48
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6564231 0.94 KDM4E (0.61) KDM4EKMT2AALDH1A1PKMLMNA
SCHEMBL6564284 0.90 KDM4E (0.68) KDM4EKMT2AALDH1A1PKMPOLB
Hydrochloric Acid SCHEMBL7554449 0.84 KDM4E (0.54) KDM4EKMT2AALDH1A1POLBLMNA
SCHEMBL6563554 0.83 KDM4E (0.59) KDM4EKMT2AALDH1A1PKMLMNA
SCHEMBL1961249 0.78 KDM4E (0.64) KDM4EKMT2AALDH1A1PKMPOLB
SCHEMBL30007934 0.77 KDM4E (0.86) KDM4EKMT2AALDH1A1PKMPOLB
SCHEMBL21247083 0.77 KDM4E (0.86) KDM4EKMT2AALDH1A1PKMPOLB
SCHEMBL6562305 0.76 KMT2A (0.58) KDM4EKMT2AALDH1A1POLBLMNA
SCHEMBL6563976 0.75 KMT2A (0.52) KMT2AALDH1A1POLBLMNAMAPT
SCHEMBL6564058 0.75 VCAM1 (0.50) KMT2AALDH1A1PKMPOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1161232-B1 HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-03-24 EP disclosed
US-20030109527-A1 Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-06-12 US disclosed
US-6500863-B1 INTERLEUKIN BINDING INHIBITORS SUCH AS N-(2-HYDROXYL-3-AMINO SULFONYL-4-CHLOROPHENYL)-N'-(2-BROMOPHENYL)UREA, USED FOR PROPHYLAXIS OF CHEMOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION 2002-12-31 US disclosed
EP-1161232-A4 HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2002-09-18 EP disclosed
EP-1161232-A1 HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2001-12-12 EP disclosed
WO-2000035442-A1 HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109527-A1 Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists CXCL8, CCR8, IL18 KDM4E 4081/4885KMT2A 3147/4885ALDH1A1 1321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.